Compare Antibiotic

arrow Created with Sketch.
arrow Created with Sketch.
10 Products

reset all

At-a-Glance

Description

FDA

CE Mark

Active Ingredients

Application

Status

Strength

remove

close Created with Sketch.
  • Formulations offer combinations of the three primary classes of medications used around the time of ocular surgery
  • One bottle reduces the total number of drops needed with an easy-to-follow postoperative regimen
  • Combined, compounded formulations can be more affordable
  • LessDrops are dispensed from the practice which offers convenience and assures surgeons that the patient has the medications they need

Combined Corticosteroid, Antibiotic, and NSAID Compounded Formulations for Postoperative Management

No (compounded formulation)

No

Formulation dependent

Topical

Prescription

Formulation dependent

remove

close Created with Sketch.
  • Mechanism of Action: Azithromycin acts by binding to the 50S ribosomal subunit of susceptible microorganisms and interfering with microbial protein synthesis.
  • Dosage: Instill 1 drop in the affected eye (s) twice daily, eight to twelve hours apart for the first two days and then instill 1 drop in the affected eye (s) once daily for the next five days.

AzaSite (azithromycin ophthalmic solution) 1% is a macrolide antibiotic indicated for the treatment of bacterial conjunctivitis caused by susceptible isolates of the following microorganisms: CDC coryneform group G, Haemophilus influenzae, Staphylococcus aureus, Streptococcus mitis group, and Streptococcus pneumoniae. The delivery vehicle is DuraSite (polycarbophil, edetate disodium, sodium chloride).

Yes

Not specified

Azithromycin

Topical

Prescription

1%

remove

close Created with Sketch.
  • Mechanism of Action: The bactericidal action of ciprofloxacin results from interference with the enzyme DNA gyrase which is needed for the synthesis of bacterial DNA.
  • Dosage: Depends on usage

Ciloxan (ciprofloxacin ophthalmic solution) 0.3% is a fluoroquinolone antibacterial active against a broad spectrum of gram-positive and gram-negative ocular pathogens. Ciprofloxacin differs from other quinolones in that it has a fluorine atom at the 6-position, a piperazine moiety at the 7-position, and a cyclopropyl ring at the 1-position.

Yes

Not specified

Ciprofloxacin HCl

Topical

Prescription

0.3%

remove

close Created with Sketch.
  • Mechanism of Action: The antibacterial action of moxifloxacin results from inhibition of the topoisomerase II (DNA gyrase) and topoisomerase IV.
  • Dosage: Instill 1 drop in the affected eye(s) 2 times daily for 7 days.

Moxeza (moxifloxacin hydrochloride ophthalmic solution) 0.5% is a topical fluoroquinolone anti-infective indicated for the treatment of bacterial conjunctivitis caused by susceptible strains of the following organisms: Aerococcus viridans*, Corynebacterium macginleyi*, Enterococcus faecalis*, Micrococcus luteus*, Staphylococcus arlettae*, Staphylococcus aureus, Staphylococcus capitis, Staphylococcus epidermidis, Staphylococcus haemolyticus, Staphylococcus hominis, Staphylococcus saprophyticus*, Staphylococcus warneri*, Streptococcus mitis*, Streptococcus pneumoniae, Streptococcus parasanguinis*, Escherichia coli*, Haemophilus influenzae, Klebsiella pneumoniae*, Propionibacterium acnes, Chlamydia trachomatis* *Efficacy for this organism was studied in fewer than 10 infections.

Yes

Not specified

Moxifloxacin hydrochloride

Topical

Prescription

0.5%

remove

close Created with Sketch.
  • Mechanism of Action: The antibacterial action of moxifloxacin results from inhibition of the topoisomerase II (DNA gyrase) andtopoisomerase IV.
  • Dosage: One drop in the affected eye 3 times a day for 7 days.

Vigamox (moxifloxacin HCl ophthalmic solution) 0.5% is an 8-methoxy fluoroquinolone anti-infective indicated for the treatment of bacterial conjunctivitis caused by susceptible strains of the following organisms: Corynebacterium species* Micrococcus luteus* Staphylococcus aureus Staphylococcus epidermidis Staphylococcus haemolyticus Staphylococcus hominis Staphylococcus warneri* Streptococcus pneumoniae Streptococcus viridans group Acinetobacter lwoffii* Haemophilus influenzae Haemophilus parainfluenzae* Chlamydia trachomatis *Efficacy for this organism was studied in fewer than 10 infections.

Yes

Not specified

Moxifloxacin

Topical

Prescription

0.5%

remove

close Created with Sketch.
  • Mechanism of Action: Not specified
  • Dosage: In mild to moderate disease, instill one or two drops into the affected eye(s) every four hours. In severe infections, instill two drops into the eye(s) hourly until improvement, following which treatment should be reduced prior to discontinuation.

Tobrex (tobramycin ophthalmic solution) 0.3% is a topical antibiotic indicated in the treatment of external infections of the eye and its adnexa caused by susceptible bacteria. Tobramycin is a water-soluble aminoglycoside antibiotic active against a wide variety of gram-negative and gram-positive ophthalmic pathogens.

Yes

Not specified

Tobramycin

Topical

Prescription

0.3%

remove

close Created with Sketch.
  • Mechanism of Action: Ofloxacin has in vitro activity against a broad range of gram-positive and gram-negative aerobic and anaerobic bacteria. Ofloxacin is bactericidal at concentrations equal to or slightly greater than inhibitory concentrations. Ofloxacin is thought to exert a bactericidal effect on susceptible bacterial cells by inhibiting DNA gyrase, an essential bacterial enzyme which is a critical catalyst in the duplication, transcription, and repair of bacterial DNA.
  • Dosage:

Ocuflox (ofloxacin ophthalmic solution) 0.3% is a fluorinated carboxyquinolone anti-infective indicated for the treatment of infections caused by susceptible strains of the following bacteria in the conditions listed below: CONJUNCTIVITIS: Staphylococcus aureus Staphylococcus epidermidis Streptococcus pneumoniae Pseudomonas aeruginosa Enterobacter cloacae Haemophilus influenzae Proteus mirabilis CORNEAL ULCERS: Staphylococcus aureus Staphylococcus epidermidis Streptococcus pneumoniae Pseudomonas aeruginosa Serratia marcescens* Propionibacterium acnes *Efficacy for this organism was studied in fewer than 10 infections

Yes

Not specified

Ofloxacin

Topical

Prescription

0.3%

remove

close Created with Sketch.
  • Mechanism of Action: The antibacterial action of gatifloxacin results from inhibition of DNA gyrase and topoisomerase IV.
  • Dosage: Patients 1 year of age or older: Instill one drop every two hours in the affected eye(s) while awake, up to 8 times on Day 1. Instill one drop two to four times daily in the affected eye(s) while awake on Days 2 through 7.

Zymaxid (gatifloxacin ophthalmic solution) 0.5% is a topical fluoroquinolone anti-infective indicated for the treatment of bacterial conjunctivitis caused by susceptible strains of the following organisms: Haemophilus influenzae, Staphylococcus aureus, Staphylococcus epidermidis, Streptococcus mitis group*, Streptococcus oralis*, Streptococcus pneumoniae *Efficacy for this organism was studied in fewer than 10 infections.

Yes

Not specified

Gatifloxacin

Topical

Prescription

0.5%

remove

close Created with Sketch.
  • Mechanism of Action: Besifloxacin is an 8-chloro fluoroquinolone with a N-1 cyclopropyl group. The compound has activity against Gram-positive and Gram-negative bacteria due to the inhibition of both bacterial DNA gyrase and topoisomerase IV.
  • Dosage: One drop in the affected eye(s) 3 times a day, four to twelve hours apart for 7 days.

Besivance (besifloxacin ophthalmic suspension) 0.6% is a fluoroquinolone indicated for the treatment of bacterial conjunctivitis caused by susceptible isolates of the following bacteria: CDC coryneform group G Corynebacterium pseudodiphtheriticum* Corynebacterium striatum* Haemophilus influenzae Moraxella lacunata* Staphylococcus aureus Staphylococcus epidermidis Staphylococcus hominis* Staphylococcus lugdunensis* Streptococcus mitis group Streptococcus oralis Streptococcus pneumoniae Streptococcus salivarius* *Efficacy for this organism was studied in fewer than 10 infections.

Yes

Not specified

Besifloxacin

Topical

Prescription

0.6%

remove

close Created with Sketch.
  • Dropless formulations are available from Imprimis' 503B outsourcing facility
  • Formulations include:
    • Tri-Moxi (Triamcinolone acetonide and moxifloxacin hydrochloride)
    • Dex-Moxi (Dexamethasone and moxifloxacin hydrochloride)
    • Dex-Moxi-Ketor (Dexamethasone, moxifloxacin hydrochloride and ketorolac)
    • Moxifloxacin
    • Hyaluronidase
    • Lidocaine/Epinephrine in BSS (PF/SF)
    • Phenylephrine/Lidocaine (PF/SF)

Dropless formulations are compounded combinations of steroid, antibiotic, and NSAID intended for use as an intracameral injection at the time of cataract surgery to minimize or eliminate the need for postoperative drops.

No (compounded formulation)

No

Formulation dependent

Injectable

Prescription

Formulation dependent